Aims & Objectives: INTRODUCTION:THE TRMOBOTIC MICROANGIOPATHY, CAN BE PRESENTED WITH SHUA, THERE ARE ADVANCES IN THE MEDICAL TREATMENT WITH ECULIZUMAB, WHICH IMPROVES MORTALITY. OBJECTIVE: TO CHARACTERIZE THE PRESENCE OF THROMBOTIC MICROANGIOPATHY IN PATIENTS WHO MET A PEAK IN THE PERIOD OF JANUARY 2010–2018. Methods STUDY: BIDIRECTIONAL OBSERVATIONAL DESCRIPTIVE STUDY Results RESULTS: IN JANUARY 2010 UNTIL JANUARY 2018, 28 PATIENTS FROM 2718 PATIENT TO PICU, 1% INCIDENCE, 57% FEMALE AND 43% MALE, 86% GREATER THAN 10 YEARS AGO.46.4% ARE AFRO-AMERICAN.THE TMA CLINICAL PRESENTATION - aHUS, 40% HAD SQUISTOCITOS, THE PLATELET AVERAGE WAS 104,925, THE ADAMST 13 PROMEDY, IN THE PATIENTS OF aHUS WAS A VALUE OF ACTIVITY OF 70%, 61% OF PATIENTS RECEIVED PLASMAFERESIS.THE CAC (ACTIVATION CONDITION OF THE COMPLEMENT), 39% LUPUS, 7% NEPHROTIC SYNDROME, 11% WITH SEPSIS. 50% RECEIVED ECULIZUMAB, 78% WERE ALIVE, 21% DID NOT SURRENDER AND 14% WHO DID NOT RECEIVE ECULIZUMAB FALLEN. Conclusions THROMBOTIC MICROANGIOPATHY, IS AN ENTITY THAT CAN BE PRESENTED IN PEDIATRIC INTENSIVE CARE, AND YOU MUST START EARLY MEDICAL TREATMENT AND CAN REDUCE MORTALITY